Overview
PillBot from Endiatx is perhaps the most audacious device in modern medical robotics: an ingestible micro-robot the size of a large pill that the patient swallows, after which a physician steers it remotely through the stomach using a joystick while watching a live video feed on a tablet. No sedation. No scope. No procedure room.
PillBot contains a miniature camera, LED illumination, and three propellers — each smaller than a grain of rice — driven by a motor system that allows 360° navigation through the stomach's fluid environment. The physician can tilt, rotate, and propel the robot to visualize any region of the gastric mucosa, including behind folds and under the cardia that conventional endoscopy struggles to reach.
Granted FDA Breakthrough Device designation, PillBot is currently completing pivotal clinical trials comparing gastric visualization adequacy to standard upper endoscopy. If cleared, it could replace millions of upper endoscopies performed annually for gastric cancer screening, H. pylori follow-up, and GERD evaluation — without requiring an endoscopy suite or anesthesia provider.
Key Technology
🚁
Tri-Propeller Propulsion
Three independent micro-propellers enable full 6-degrees-of-freedom navigation through gastric fluid. Each propeller blade is smaller than a grain of rice.
🎮
Remote Joystick Control
Physician steers PillBot from any location via tablet + joystick. Live HD video streams in real-time, enabling telemedicine-based gastric evaluation without patient travel.
📷
Live HD Camera
High-definition wide-angle camera with LED illumination streams continuous color video, providing visualization quality approaching diagnostic endoscopy.
♻️
Fully Biodegradable
After the procedure, PillBot passes naturally through the GI tract and is designed to fully dissolve — eliminating any concern about retained hardware.
Clinical Pipeline
Breakthrough Device
FDA Breakthrough Device Designation
FDA recognized PillBot as a Breakthrough Device for gastric visualization — acknowledging its potential to address an unmet need in accessible, sedation-free stomach imaging at scale.
Ongoing Trial
Pivotal Trial vs. Standard Endoscopy
IDE pivotal trial comparing PillBot gastric visualization adequacy, pathology detection rate, and patient experience vs. conventional upper endoscopy. Primary endpoint: non-inferiority for visualization of all gastric anatomic regions.
Early Results
First-in-Human Safety Data
Initial FIH study in healthy volunteers demonstrated successful navigation of all gastric regions in 100% of subjects, with no adverse events. Remote operation from separate room validated as technically feasible.
Timeline
2018
Endiatx founded; initial PillBot prototypes developed
2021
First-in-human procedures completed; proof-of-concept data published
2022
FDA Breakthrough Device designation granted
2024–25
IDE pivotal trial enrolling; telemedicine-guided procedure model validated
2026
Anticipated FDA De Novo submission pending pivotal trial completion